Phar­ma com­pa­nies soft­en tone on full IRA im­pact

De­spite the phar­ma­ceu­ti­cal in­dus­try’s heavy crit­i­cism of the In­fla­tion Re­duc­tion Act, John­son & John­son, Pfiz­er and Bris­tol My­ers Squibb re­cent­ly down­played the leg­is­la­tion’s over­all im­pact …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER